Introduction {#sec1}
============

Attention-deficit hyperactivity disorder (ADHD)---characterized by symptoms of inattention, impulsivity, and/or hyperactivity---and Autism Spectrum Disorder (ASD)---characterized by difficulties with social interaction, communication, and restricted and repetitive behavior---are co-occurring neurodevelopmental disorders ([@bib1]). The prevalence of ADHD has been estimated to be 5.9%--7.1% in childhood and adolescence ([@bib6]) and globally, ∼1 in 130 individuals had ASD in 2010 ([@bib7]). The fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM) requires an age of onset of symptoms before 12 y of age for the diagnosis of ADHD. For an ASD diagnosis, symptoms must be present in "early childhood" ([@bib8]). The etiology of these 2 neurodevelopmental disorders is yet to be elucidated, but it is assumed that there is an (overlapping) heritable component to these conditions ([@bib9]).

Given the neurobiological origin of these disorders, research has focused on investigating whether the maternal supply of thyroid hormone to the fetus is associated with childhood ADHD and ASD. Thyroid hormone regulates neuronal proliferation, differentiation, migration, synapse formation, and myelination in the fetal brain ([@bib10], [@bib11]) and during early pregnancy the fetus acquires thyroid hormone solely from the mother ([@bib12]). Epidemiological studies do not consistently show an association between maternal thyroid function and childhood ADHD ([@bib13]). In our previously conducted meta-analysis of individual participant data, we reported no consistent evidence linking maternal thyroid-stimulating hormone (TSH) and free thyroxine (FT4) concentrations with child ADHD ([@bib21]). Maternal hypothyroidism and overt hyperthyroidism have been associated with a greater risk of diagnosed ASD ([@bib15], [@bib20]), and a low maternal FT4 concentration measured in the first 18 wk of pregnancy has been associated with a greater risk of autistic traits ([@bib22]). In a previous study, we also reported a suggestive association of both hypothyroxinemia, characterized by low FT4 and normal TSH, and high FT4 with a greater risk of autistic traits within the clinical range ([@bib23]). It is unclear whether iodine deficiency underpins the association between mild thyroid dysfunction and these neurodevelopmental disorders.

Iodine deficiency in pregnant populations, which is defined by the WHO as a median urinary iodine concentration (UIC) \<150 μg/L, is common ([@bib24], [@bib25]). Severe iodine deficiency during pregnancy has been associated with severe health outcomes including goiter, abortion, stillbirths, and intellectual disability in the offspring ([@bib26]). Mild-to-moderate iodine deficiency---which has been defined in pregnant populations as a median UIC between 50 and 150 μg/L ([@bib27])---before conception and during pregnancy has been associated with neurodevelopmental outcomes, including lower child intelligence quotient (IQ) scores ([@bib28]). A study suggested that maternal iodine status may affect child outcomes in a dose-dependent manner, but the authors could not test whether the effects of iodine availability for the developing brain were related to impaired maternal thyroid function in pregnancy ([@bib30]). Investigating such underlying mechanisms may elucidate which subgroups of pregnant women may be at a high risk of giving birth to children with neurobehavioral problems.

Given the important role of iodine for thyroid hormone production and fetal brain development, maternal iodine deficiency during a critical developmental window may potentially increase the risk of neurodevelopmental disorders in the offspring ([@bib31]). Studies on the association between maternal iodine status during pregnancy and ADHD or ASD are rare. A small study performed in Italy (*n* = 27) showed that 68.7% of children (11 out of 16) born to mildly-to-moderately iodine-deficient mothers---more than half of whom also suffered from hypothyroxinemia---were diagnosed with ADHD, whereas none of the children born to mothers originating from an iodine-sufficient area were diagnosed with ADHD ([@bib32]). In a larger Norwegian cohort, maternal iodine intake \<200 μg/d (which is lower than currently recommended in pregnancy) ([@bib33]) as reported by a questionnaire at week 22 of gestation was also associated with higher ADHD symptoms but not with ADHD diagnosis ([@bib34]). However, in that same cohort, the use of iodine-containing supplements was not associated with a lower risk of ADHD or a lower symptom score. In fact, children born to mothers with low iodine intake and who initiated iodine supplementation in the first trimester of pregnancy had a higher risk of ADHD ([@bib34]). To the best of our knowledge, maternal iodine status has not been studied in relation to childhood ASD or autistic traits in large, prospective cohort studies. Against this background we carefully posit that iodine deficiency is related to a higher likelihood of ADHD or ASD. This hypothesis implies a threshold, i.e., nonlinear relation, because we have no evidence that, if sufficient, iodine is more protective at higher concentrations.

The primary aim of this study was to investigate the association of maternal iodine status during pregnancy with child ADHD and autistic traits. A second aim was to examine whether maternal iodine status modifies the association between maternal thyroid function and neurobehavioral outcomes.

Methods {#sec2}
=======

Study design and population {#sec2-1}
---------------------------

The study was embedded in 3 population-based birth cohorts: Generation R (Netherlands) ([@bib35]), the INfancia y Medio Ambiente Project (INMA) (Spain: Valencia, Sabadell, and Gipuzkoa) ([@bib36]), and the Avon Longitudinal Study of Parents and Children (ALSPAC) (United Kingdom) ([@bib37], [@bib38]). Briefly, in Generation R, 9778 mothers from Rotterdam, Netherlands with a delivery date between April 2002 and January 2006 were enrolled. The INMA Project consists of 7 birth cohorts in Spain, of which 3 were included in the current research: Valencia (*n* = 855), Sabadell (*n* = 657), and Gipuzkoa (*n* = 638). Pregnant women from these 3 regions were enrolled from November 2003 until June 2005, July 2004 until July 2006, and April 2006 until January 2008, respectively. In ALSPAC, pregnant women resident in Avon, United Kingdom with expected delivery dates between April 1991 and December 1992 were invited to take part in the study. The initial number of pregnancies enrolled was 14,541, of which 13,998 children were alive at 1 y of age. The ALSPAC website contains all the data that are available, which can be accessed via a searchable data dictionary and variable search tool ([@bib39]). Inclusion criteria for the current study were data availability of measures of urinary iodine and creatinine during pregnancy and an assessment of ADHD symptoms and/or autistic traits in childhood. Exclusion criteria were multiple fetuses, fertility treatment, thyroid-interfering medication use, and pre-existing thyroid disease ([**Figure 1**](#fig1){ref-type="fig"}). Women with undiagnosed thyroid disorder were not excluded. Ethical approval was obtained before recruitment from a number of bodies: the Medical Ethical Committee of the Erasmus Medical Center (Generation R), Ethical Committee of the Municipal Institute of Medical Investigation and the Ethical Committees of the hospitals involved in the study (INMA), and the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees; approval by parents or guardians of the children was given via a signed informed-consent form. The current study did not follow a prespecified registered protocol.

![Flowchart of the study population. ADHD, attention-deficit hyperactivity disorder; ALSPAC, Avon Longitudinal Study of Parents and Children; INMA, INfancia y Medio Ambiente; UIC, urinary iodine concentration; UI/Creat, urinary iodine-to-creatinine ratio.](nxaa051fig1){#fig1}

Maternal iodine status {#sec2-2}
----------------------

UIC and creatinine were measured in spot-urine samples stored at −20°C after collection. UIC was measured in 3 different laboratories using different assays. Detailed information on the measurement methods is described elsewhere ([@bib29]). To take into account hydration status, we used the iodine-to-creatinine ratio (UI/Creat) as a measure of iodine status. Owing to the possible use of iodine-containing test strips in ALSPAC, contamination of some urine samples in ALSPAC was suspected ([@bib40]); hence, in this cohort only, women with a UIC \>500 μg/L and/or a UI/Creat \>700 μg/g were excluded from the analyses ([Figure 1](#fig1){ref-type="fig"}). These cutoffs were based on previous work in ALSPAC and from other studies of pregnant women in the United Kingdom ([@bib30], [@bib41], [@bib42]).

Maternal thyroid function {#sec2-3}
-------------------------

In a previous study, we investigated whether maternal thyroid function was associated with child ADHD ([@bib21]) and autistic traits ([@bib23]). For the second aim of the current study---to test whether iodine modifies the association between thyroid function and neurodevelopmental outcomes---we used previously measured TSH and FT4 in maternal serum samples and created interaction terms with UI/Creat. In Generation R, serum samples were centrifuged and stored at −80°C after collection at a mean ± SD gestational age of 13.2 ± 1.8 wk. FT4 and TSH were measured using the Vitros ECi Immunodiagnostic System (Ortho Clinical Diagnostics) ([@bib43]). Thyroid peroxidase antibodies (TPOAbs) were also measured using the Phadia 250 immunoassay analyzer (Phadia AB) and the manufacturer cutoff for TPOAb positivity was a thyroid peroxidase (TPO) titer ≥60 IU/mL. In INMA, serum samples were stored at −80°C after collection at a mean ± SD gestational age of 13.2 ± 1.4 wk. FT4 and TSH were measured using a solid-phase, time-resolved sandwich fluoro-immunoassay (AutoDEL-FIA, PerkinElmer Life and Analytical Sciences, Wallac Oy) and a lanthanide metal europium label ([@bib44]). TPOAbs were not measured. In ALSPAC, serum samples were collected at a mean ± SD gestational age of 10.3 ± 2.7 wk and stored at −20°C. FT4, TSH, and TPOAb measurements were performed using the Abbott Architect i2000 ([@bib17]). The manufacturer cutoff for TPOAb positivity was a TPO titer ≥6 IU/mL.

ADHD symptoms {#sec2-4}
-------------

In Generation R, ADHD symptoms were rated by parents at a mean ± SD age of 5.8 ± 0.2 y using the DSM-oriented scale Attention-Deficit/Hyperactivity of the Child Behavioral Checklist for ages 1.5--5 y (CBCL1½--5) ([@bib45]). This scale consists of 6 questions on a 3-point Likert scale, the sum score constituting the total ADHD symptom rating. The CBCL1½--5 was chosen at the time of follow-up, because the majority of children were expected to be younger than 6 y old at assessment and the CBCL1½--5 was collected at 2 earlier time points (i.e., 18 mo and 3 y) and thus chosen for continuity reasons. All subscales of the CBCL1½--5 showed Cronbach\'s αs ranging from 0.60 to 0.89, and are the same for 5-y-old children and children older than 5 y ([@bib46]). Next, positive screens \[i.e., children who scored in the top 15 percentiles of the CBCL1½--5 total problem score and/or in the top 2% of the syndrome scale scores; scores above the 97th percentile are in the clinical range ([@bib45])\] were invited for further assessment with the Diagnostic Interview Schedule for Children---Young Child version (DISC-YC) ([@bib47]). This DSM-IV-based interview was used to establish an ADHD diagnosis and was conducted with parents or caregivers by trained research assistants at a mean ± SD age of 6.6 ± 0.4 y. More detailed information on the procedures and the DISC-YC assessment is described elsewhere ([@bib48]).

In INMA, ADHD symptoms were assessed by teachers by means of the ADHD criteria of the DSM fourth edition (DSM-IV) ([@bib49]) at a mean ± SD age of 5.9 ± 0.3 y in Valencia, 4.4 ± 0.3 y in Sabadell, and 4.4 ± 0.2 y in Gipuzkoa. The DSM-IV consists of questions on 9 inattention symptoms and 9 hyperactivity-impulsivity symptoms on a 4-point Likert scale. The sum score of these 18 questions constituted the total symptom score. Based on the symptom criteria of the DSM-IV, ADHD was diagnosed when the child had ≥6 inattention and/or hyperactivity-impulsivity symptoms.

In ALSPAC, inattention and hyperactivity symptoms were assessed through a parental semistructured interview as part of the Development and Well-Being Assessment (DAWBA) at a mean ± SD age of 7.7 ± 0.1 y ([@bib50]). The total symptom score consisted of the sum of the inattention and hyperactivity-impulsivity symptoms. In addition, teachers completed the DAWBA questionnaire for half of all children ([@bib51]). Data from the interview and/or questionnaire were used to assign an ADHD diagnosis following the DSM-IV symptom criteria.

Autistic traits {#sec2-5}
---------------

Autistic traits in children were measured by assessing the number of symptoms common to ASD. In Generation R, parents completed the Social Responsiveness Scale (SRS) questionnaire at a mean ± SD child age of 5.9 ± 0.2 y ([@bib52]). We used the short version with 18 items, including 4-point Likert-scale questions on social cognition, social communication, and stereotypical behavior. The correlation between the full SRS score and the shortened SRS version is 0.93--0.99, as shown in 3 different studies ([@bib53]). The complete 18-item version of the SRS is provided elsewhere ([@bib54]).

In INMA, autistic traits were assessed using the Childhood Autism Spectrum Test, which was administered to the parents by a psychologist at a mean ± SD child age of 5.8 ± 0.2, 4.5 ± 0.2, and 4.5 ± 0.1 y in the regions of Valencia, Sabadell, and Gipuzkoa, respectively ([@bib55]). The sum score of 31 items, which could be answered with only 2 response options, yielded the total sum score.

In ALSPAC, autistic traits were assessed using the Social Communication Disorder Checklist by parents at a mean ± SD child age of 7.6 ± 0.1 y ([@bib56]). This questionnaire with a total of 12 items on a 3-point Likert scale covered questions on social reciprocity, nonverbal skills, pragmatic language usage, and functional impairment. The ratings of these 12 items were summed to obtain a total score.

Covariates {#sec2-6}
----------

Covariates were chosen based on prior knowledge and a directed acyclic graph (**[Supplemental Figure 1](#sup1){ref-type="supplementary-material"}**), and available for all cohorts. Information on maternal age, parity (0, 1, ≥2), prepregnancy BMI, smoking during pregnancy (never, smoked in the beginning or until pregnancy confirmed, continued smoking), ethnicity/country of birth (cohort-specific categories), and maternal educational level (low, middle, high) was collected through questionnaires during pregnancy. Gestational age at urine and blood sampling was defined using ultrasound and/or last menstrual period. Information on sex of the child was obtained from community midwives, obstetricians, hospital registries, clinical records, or questionnaires. Child age was obtained at the time of the ascertainment of ADHD symptoms and autistic traits. All further analyses were adjusted for the mentioned covariates.

Statistical analyses {#sec2-7}
--------------------

We imputed missing values of the covariates (0%--11.3% missing; see [**Table 1**](#tbl1){ref-type="table"}) by chained equations and generated 25 imputed data sets ([@bib57]). Because our study population differed from those mother--child pairs who were lost to follow-up (**[Supplemental Table 1](#sup1){ref-type="supplementary-material"}**), we used inverse probability weighting ([@bib58]). First, we predicted the probability of participation in the study with the characteristics of all participants at recruitment, and then applied the inverse of this probability as weights in all analyses.

###### 

Population characteristics^[1](#tb1fn1){ref-type="table-fn"}^

                                                            Generation R (*n* = 1634)   INMA (*n* = 1293)   ALSPAC (*n* = 2619)                              
  --------------------------------------------------------- --------------------------- ------------------- --------------------- ------------------- ------ -------------------
  ADHD,^[2](#tb1fn2){ref-type="table-fn"}^ %                1588                        3.5                 1066                  5.0                 2611   1.7
  Autistic traits ≥93rd percentile, %                       1291                        7.4                 1111                  8.5                 2585   8.0
  Iodine status, all women                                                                                                                                   
   UI/Creat, μg/g                                           1634                        212 (153--291)      1293                  168 (110--255)      2619   131 (88--203)
   UI/Creat \<150 μg/g, %                                   1634                        23.4                1293                  43.1                2619   58.7
   Gestational age, wk                                      1634                        16.1 (15.0--17.3)   1293                  20.6 (19.5--21.8)   2619   13.0 (9.2--17.0)
  Iodine status at ≤18 wk                                                                                                                                    
   UI/Creat, μg/g                                           1555                        211 (141--309)      1161                  154 (97--259)       2403   125 (85--198)
   UI/Creat \<150 μg/g, %                                   1555                        28.0                1161                  48.5                2403   61.0
   Gestational age, wk                                      1555                        12.9 (12.1--14.4)   1161                  12.9 (12.3--13.7)   2403   12.0 (9.0--15.0)
  Iodine status at ≤14 wk                                                                                                                                    
   UI/Creat, μg/g                                           1082                        210 (141--303)      952                   157 (99--265)       1530   111 (75--165)
   UI/Creat \<150 μg/g, %                                   1082                        28.0                952                   47.5                1530   69.7
   Gestational age, wk                                      1082                        12.4 (11.6--13.1)   952                   12.7 (12.1--13.3)   1530   10.0 (8.0--12.0)
  Maternal thyroid function                                                                                                                                  
   TSH, mIU/L                                               1451                        1.32 (0.81--2.01)   1251                  1.25 (0.84--1.80)   965    0.98 (0.64--1.40)
   FT4, pmol/L                                              1459                        14.5 (13.0--16.4)   1253                  10.6 (9.7--11.6)    970    16.2 (14.9--17.6)
   TPOAb positivity, %                                      1470                        5.4                                       NA                  973    12.7
   Gestational age, wk                                      1460                        13.2 ± 1.8          1252                  13.2 ± 1.4          979    10.3 ± 2.7
  Female sex, %                                             1634                        50.1                1292                  49.8                2619   50.7
  Educational level,^[3](#tb1fn3){ref-type="table-fn"}^ %   1580                                            1289                                      2570   
   Low                                                                                  6.5                                       21.0                       18.7
   Middle                                                                               39.7                                      41.1                       62.8
   High                                                                                 53.9                                      37.6                       18.5
  Maternal ethnicity/country of birth, %                    1633                                            1291                                      2562   
   Majority^[4](#tb1fn4){ref-type="table-fn"}^                                          56.8                                      93.5                       98.6
   Minority^[5](#tb1fn5){ref-type="table-fn"}^                                          43.2                                      6.5                        1.4
  Maternal age, y                                           1634                        30.8 ± 4.6          1281                  31.6 ± 3.9          2619   28.7 ± 4.4
  Parity, %                                                 1634                                            1291                                      2545   
   0                                                                                    60.0                                      56.2                       47.6
   1                                                                                    28.7                                      37.1                       34.0
   ≥2                                                                                   11.3                                      6.6                        18.5
  Smoking during pregnancy, %                               1490                                            1293                                      2586   
   Never                                                                                76.6                                      69.9                       84.4
   In the beginning of pregnancy                                                        10.0                                      13.2                       3.7
   Continued                                                                            13.4                                      16.9                       11.9
  Prepregnancy BMI, kg/m^2^                                 1450                        22.6 (20.8--25.1)   1293                  22.5 (20.8--25.0)   2417   22.2 (20.5--24.4)

Values are means ± SDs, medians (IQRs), or percentages. Values are shown without multiple imputation (percentages of missing data: 0.0%, 0.1%, and 0.0% for child sex; 3.3%, 0.3%, and 1.9% for maternal education; 0.1%, 0.2%, and 2.1% for maternal ethnicity/country of birth; 0.1%, 0.9%, and 2.2% for maternal age; 0.0%, 0.2%, and 2.8% for parity; 8.8%, 1.3%, and 1.3% for smoking; and 11.3%, 0.0%, and 7.7% for prepregnancy BMI in Generation R, INMA, and ALSPAC, respectively). ADHD, attention-deficit hyperactivity disorder; ALSPAC, Avon Longitudinal Study of Parents and Children; FT4, free thyroxine; INMA, INfancia y Medio Ambiente; NA, not available; TPOAb, thyroid peroxidase antibody; TSH, thyroid-stimulating hormone; UI/Creat, urinary iodine-to-creatinine ratio.

ADHD diagnosis was established by interview but not confirmed by medical-record data.

Generation R: low = no education or primary; middle = secondary phase 1 and 2; high = higher phase 1 and 2; INMA: low = no education, unfinished primary, or primary; middle = secondary; high = university degree; ALSPAC: low = no qualification, certificate of secondary education, or vocational; middle = O level or A level; high = a degree.

Defined as Dutch (Generation R), Spanish (INMA), or white (ALSPAC).

Defined as non-Dutch (Generation R), non-Spanish (INMA), or nonwhite (ALSPAC).

A proportion of women had multiple measurements of UIC and creatinine throughout pregnancy (**[Supplemental Table 2](#sup1){ref-type="supplementary-material"}**). To have a measure of average fetal iodine availability during the course of pregnancy, we calculated a geometric mean of the UI/Creat values for these women, which is a measure that is less susceptible to outliers than the arithmetic mean. A geometric mean was also calculated to have a measure of average gestational age at the time of measurement. The continuous UI/Creat measures were transformed by the natural logarithm to achieve a normal distribution. We grouped women into 2 groups: those with a UI/Creat \<150 μg/g or a UI/Creat ≥150 μg/g. The former cutoff relates to iodine deficiency based on the WHO median UIC classification ([@bib33]), and when adjusted for creatinine has been used previously ([@bib28], [@bib59], [@bib60]).

We studied the associations of UI/Creat \<150 μg/g and UI/Creat on a continuous scale with ADHD or a high autistic-trait score, the latter defined as a score ≥93rd percentile, using multivariable logistic regression in each cohort separately. The reference group consisted of women with a UI/Creat ≥150 μg/g. The 93rd-percentile cutoff was derived from a Dutch norm sample as a cutoff score to define children with problem behavior using the DSM-oriented scales of the CBCL ([@bib61]). In the absence of a normative sample in INMA and ALSPAC, we also used the 93rd-percentile cutoff scores in these 2 cohorts. We did not use a cutoff that defines autistic traits within the clinical range, as we have used previously ([@bib23]), because of the low prevalence of children with such a score. The cohort-specific estimates were combined using random-effects meta-analysis (termed "pooled analysis" in this article). Statistical heterogeneity was explored and quantified using the Cochran Q test and the *I*^2^ statistic ([@bib62]). Because the fetus is largely dependent on the thyroidal state of the mother during early pregnancy ([@bib63]), we wanted to investigate whether there is a particularly high risk of neurobehavioral outcomes in childhood in the offspring born to women with (mild-to-moderate) iodine deficiency in early pregnancy. Therefore, we repeated the analysis in those mother--child pairs, in which the mothers had ≥1 measure of urinary iodine at ≤18 weeks of gestation and in those with ≥1 measure at ≤14 weeks of gestation. The pregnancy period of ≤14 wk was chosen because our previous study indicated that low iodine status within this time window, but not thereafter, was associated with low child verbal IQ ([@bib29]). For women with 2 available measures of urinary iodine and creatinine in early pregnancy (≤18 wk: Generation R, *n* = 0; INMA, *n* = 0; ALSPAC, *n* = 306; ≤14 wk: Generation R, *n* = 0; INMA, *n* = 0; ALSPAC, *n* = 27), a geometric mean of the 2 UI/Creat values and of the gestational age at the time of measurement was calculated.

We conducted several sensitivity analyses supporting the primary aim of the current study. First, we repeated all analyses using the UIC as an indicator of iodine status instead of UI/Creat. For these UIC analyses we re-added mother--child pairs that were excluded from the UI/Creat analyses due to missing creatinine data (*n* = 38 mother--child pairs from INMA) or those that were excluded due to possible contamination of urine samples (i.e., UI/Creat \>700 μg/g; *n* = 95 mother--child pairs from ALSPAC). Although correcting UIC for creatinine takes into account the hydration status and better reflects the 24-h iodine excretion than UIC alone ([@bib64]), the median UIC is recommended by the WHO to assess the iodine status of a population ([@bib33]). Second, considering that the distribution of ADHD symptoms and autistic traits in a population is on a continuous spectrum, we also investigated the association of UI/Creat, either \<150 μg/g or on a continuous scale, with ADHD symptoms and autistic traits as count scores using negative binomial regression models. The symptom scores were not comparable between cohorts because they did not share a common metric and therefore the associations were analyzed and presented by cohort.

Next, we studied whether the associations of maternal FT4 and TSH with ADHD and a high autistic-trait score differed depending on the iodine status of the mother. First, FT4 and TSH concentrations were logarithmically transformed to approach normality. To take into account the varying assays, cohort-specific SD scores were calculated with a mean of 0 and an SD of 1. These SD scores were based on the data of TPOAb-negative women or all women if TPOAb status was unknown (i.e., in INMA). FT4 and TSH SD scores outside the mean ± 4 SD range were considered as outliers and excluded from further analyses. The associations of FT4 SD scores and TSH SD scores with ADHD and a high-autistic trait score were assessed using multivariable logistic regression per cohort. The cohort-specific effect estimates were combined in random-effects meta-analyses ([@bib65]). The time of thyroid function measurements coincided in a high proportion of women with the time of the first available measurement of UI/Creat. We therefore used the latter to stratify these associations into 2 groups of mother--child pairs: those in which the mother had a UI/Creat \<150 μg/g and those that had a UI/Creat value ≥150 μg/g. Interaction of FT4 or TSH SD scores with UI/Creat in relation to ADHD and autistic traits was also formally tested per cohort by adding a product interaction term in the cohort-specific models. As a sensitivity analysis, we examined whether excluding TPOAb-positive women changed the association of maternal thyroid function with ADHD and autistic traits. All statistical analyses were performed in STATA version 15.0 (StataCorp.). Values were considered statistically significant at *P \<* 0.05.

Results {#sec3}
=======

A total of 5546 mother--child pairs were included ([Figure 1](#fig1){ref-type="fig"}). The iodine status of the 3 cohorts differed; the median UI/Creat in pregnancy was 212 μg/g in Generation R, 168 μg/g in INMA, and 131 μg/g in ALSPAC ([Table 1](#tbl1){ref-type="table"}). The median UIC was 178 μg/L \[adequate intake, i.e., median UIC in the range 150--249 μg/L ([@bib33])\], 134 μg/L \[inadequate intake, i.e., median UIC \<150 μg/L ([@bib33])\], and 98 μg/L (inadequate intake) in Generation R, INMA, and ALSPAC, respectively. A total of 1290 (78.9%), 929 (71.8%), and 412 (15.7%) women had 2--4 repeated measurements of UI/Creat in Generation R, INMA, and ALSPAC, respectively ([Supplemental Table 2](#sup1){ref-type="supplementary-material"}). Women with repeated measures in INMA and ALSPAC differed in several characteristics from those that only provided a single urine sample. This may reflect the fact that repeated measures are conditional to early study inclusion. Moreover, the concentration of the first UI/Creat sample of women with repeated measurements in ALSPAC was lower than that of later measurements, and also lower than that of women with only a single measurement, possibly reflecting gestational changes.

ADHD {#sec3-1}
----

Children born to women with a UI/Creat \<150 μg/g during pregnancy (i.e., "iodine deficiency") were not at greater risk of ADHD in the pooled analysis than those born to women with UI/Creat ≥150 μg/g (OR: 1.2; 95% CI: 0.7, 2.2; *P =* 0.56; *I*^2^ = 66.5%; *P* for heterogeneity = 0.051) ([**Figure 2**](#fig2){ref-type="fig"}). In Generation R, UI/Creat \<150 μg/g was associated with a 2.0-fold higher risk of ADHD (95% CI: 1.2, 3.5; *P =* 0.014) ([Figure 2](#fig2){ref-type="fig"}). Our random-effects meta-analysis also shows no association of UI/Creat \<150 μg/g in the gestational age period of ≤18 wk or ≤14 wk with ADHD ([Figure 2](#fig2){ref-type="fig"}). When UI/Creat was analyzed continuously, there was no association between UI/Creat and ADHD. Again, only in Generation R a 1-unit increase in the natural logarithm of UI/Creat was associated with a 60% lower relative risk of ADHD (OR: 0.4; 95% CI: 0.2, 0.7; *P* \< 0.001; **[Supplemental Figure 2](#sup1){ref-type="supplementary-material"}**). UIC was not associated with ADHD (**[Supplemental Figures 3](#sup1){ref-type="supplementary-material"}** and **4**). Similarly to UI/Creat, lower UIC was associated with a higher risk of ADHD in the Generation R cohort only ([Supplemental Figures 3](#sup1){ref-type="supplementary-material"} and [4](#sup1){ref-type="supplementary-material"}). UI/Creat, modeled either categorically or on a continuous scale, was not associated with ADHD symptoms on a continuous scale in any of the 3 cohorts (**[Supplemental Tables 3](#sup1){ref-type="supplementary-material"}** and **[4](#sup1){ref-type="supplementary-material"}**, respectively).

![Association of maternal UI/Creat \<150 μg/g with child ADHD. Associations depicted as OR (dot) with 95% CI per cohort and overall associations as estimated by random-effects meta-analysis (diamond) in (A) all mother--child pairs, (B) those with ≥1 measure of UI/Creat at ≤18 weeks of gestation, and (C) those with ≥1 measure of UI/Creat at ≤14 weeks of gestation. Analyses adjusted for maternal age, parity, prepregnancy BMI, smoking during pregnancy, ethnicity/country of birth, maternal educational level, gestational age at urine sampling, child sex, child age, and subcohort in INMA. n = children with ADHD, N = children without ADHD. ADHD, attention-deficit hyperactivity disorder; ALSPAC, Avon Longitudinal Study of Parents and Children; INMA, INfancia y Medio Ambiente; UI/Creat, urinary iodine-to-creatinine ratio.](nxaa051fig2){#fig2}

A high autistic-trait score {#sec3-2}
---------------------------

Children born to women with UI/Creat \<150 μg/g during pregnancy were not at greater risk of a high autistic-trait score (OR: 0.8; 95% CI: 0.6, 1.1; *P* = 0.22; *I*^2^ = 30.4%; *P* for heterogeneity = 0.24) in the pooled analysis than those born to women with UI/Creat ≥150 μg/g ([**Figure 3**](#fig3){ref-type="fig"}). In the Generation R cohort only, UI/Creat \<150 μg/g was associated with a 50% lower relative risk of a high autistic-trait score (OR: 0.5; 95% CI: 0.3, 1.0; *P* = 0.035) ([Figure 3](#fig3){ref-type="fig"}). Further pooled analyses in those with a urinary iodine assessment in the gestational age period of ≤18 wk or ≤14 wk also showed no association between UI/Creat \<150 μg/g and a high autistic-trait score ([Figure 3](#fig3){ref-type="fig"}). Next, we performed an analysis of continuously modeled UI/Creat concentrations; a 1-unit increase in the natural logarithm of UI/Creat was associated with a 1.2-fold higher risk of a high autistic-trait score (95% CI: 1.0, 1.5; *P* = 0.044; *I*^2^ = 0.0%; *P* for heterogeneity = 0.63) (**[Supplemental Figure 5](#sup1){ref-type="supplementary-material"}**). The latter effect estimates were similar when this association was investigated in the 2 early time periods during pregnancy ([Supplemental Figure 5](#sup1){ref-type="supplementary-material"}). UIC, modeled either categorically or continuously, was not associated with a high autistic-trait score in any of the cohorts (**[Supplemental Figures 6](#sup1){ref-type="supplementary-material"}** and **[7](#sup1){ref-type="supplementary-material"}**, respectively). UI/Creat, modeled either as \<150 μg/g or on a continuous scale, was not associated with autistic traits on a continuous scale in any of the 3 cohorts ([Supplemental Tables 3](#sup1){ref-type="supplementary-material"} and [4](#sup1){ref-type="supplementary-material"}, respectively).

![Association of maternal UI/Creat \<150 μg/g with a high child autistic-trait score ≥93rd percentile. Associations depicted as OR (dot) with 95% CI per cohort and overall associations as estimated by random-effects meta-analysis (diamond) in (A) all mother--child pairs, (B) those with ≥1 measure of UI/Creat at ≤18 weeks of gestation, and (C) those with ≥1 measure of UI/Creat at ≤14 weeks of gestation. Analyses adjusted for maternal age, parity, prepregnancy BMI, smoking during pregnancy, ethnicity/country of birth, maternal educational level, gestational age at urine sampling, child sex, child age, and subcohort in INMA. n = children with a score \>93rd percentile, N = children with a score \<93rd percentile. ALSPAC, Avon Longitudinal Study of Parents and Children; INMA, INfancia y Medio Ambiente; UI/Creat, urinary iodine-to-creatinine ratio.](nxaa051fig3){#fig3}

Maternal thyroid function and child ADHD and autistic traits {#sec3-3}
------------------------------------------------------------

Neither FT4 nor TSH concentrations nor TPOAb positivity rates differed between women with UI/Creat \<150 μg/g or ≥150 μg/g (**[Supplemental Table 5](#sup1){ref-type="supplementary-material"}**). A 1-unit increase in the FT4 SD score was associated with a 1.3-fold higher risk of ADHD (95% CI: 1.0, 1.6; *P* = 0.017; *I*^2^ = 0.0%; *P* for heterogeneity = 0.93) ([**Table 2**](#tbl2){ref-type="table"}). This association was not modified by UI/Creat (*P* for interaction = 0.70, 0.40, 0.96, in Generation R, INMA, and ALSPAC, respectively). TSH was not associated with ADHD (OR: 0.8; 95% CI: 0.7, 1.0; *P* = 0.11; *I*^2^ = 0.0%; *P* for heterogeneity = 0.63) ([Table 2](#tbl2){ref-type="table"}). This association was not modified by UI/Creat (*P* for interaction = 0.57, 0.54, and 0.09 in Generation R, INMA, and ALSPAC, respectively).

###### 

Association of FT4 and TSH with ADHD in all mother--child pairs and stratified by groups of UI/Creat^[1](#tb2fn1){ref-type="table-fn"}^

                                           ADHD^[2](#tb2fn2){ref-type="table-fn"}^                                                                                 
  ------------------------- -------------- ----------------------------------------- ----------------- ------- -------------- ---------- ----------------- ------- -------------
  All mother--child pairs   Pooled         117/3295                                  1.3 (1.0, 1.6)    0.017   0.0% (0.93)    114/3266   0.8 (0.7, 1.0)    0.11    0.0% (0.63)
                            Generation R   51/1362                                   1.3 (0.9, 1.7)    0.13    0.70           50/1359    0.8 (0.6, 1.0)    0.08    0.57
                            INMA           53/979                                    1.2 (0.9, 1.7)    0.16    0.40           52/970     0.9 (0.6, 1.3)    0.57    0.54
                            ALSPAC         13/954                                    1.4 (0.8, 2.4)    0.22    0.96           12/937     1.0 (0.5, 2.1)    0.93    0.09
  UI/Creat \<150 μg/g       Pooled         57/1497                                   1.3 (1.0, 1.7)    0.08    0.0% (0.80)    56/1481    0.8 (0.6, 1.1)    0.15    0.0% (0.75)
                            Generation R   21/381                                    1.5 (0.9, 2.4)    0.12    NA             21/379     0.8 (0.5, 1.3)    0.43    NA
                            INMA           28/477                                    1.3 (0.8, 1.9)    0.31    NA             27/472     0.7 (0.4, 1.2)    0.15    NA
                            ALSPAC         8/639                                     1.1 (0.5, 2.3)    0.80    NA             8/630      0.9 (0.4, 2.2)    0.89    NA
  UI/Creat ≥150 μg/g        Pooled         60/1798                                   1.4 (0.9, 2.2)    0.13    39.4% (0.19)   58/1785    0.8 (0.6, 1.1)    0.22    7.9% (0.34)
                            Generation R   30/981                                    1.1 (0.7, 1.7)    0.59    NA             29/980     0.7 (0.4, 1.0)    0.049   NA
                            INMA           25/502                                    1.4 (0.9, 2.2)    0.17    NA             25/498     1.0 (0.6, 1.6)    0.98    NA
                            ALSPAC         5/315                                     3.8 (1.1, 13.1)   0.038   NA             \<5/307    1.5 (0.2, 10.3)   0.68    NA

The pooled estimate represents the overall effect estimates (OR with 95% CI) calculated with a random-effects meta-analysis. ADHD, attention-deficit hyperactivity disorder; ALSPAC, Avon Longitudinal Study of Parents and Children; FT4, free thyroxine; INMA, INfancia y Medio Ambiente; NA, not applicable; TSH, thyroid-stimulating hormone; UI/Creat, urinary iodine-to-creatinine ratio.

ADHD diagnosis was established by interview but not confirmed by medical-record data.

n represents the number of children with ADHD; N represents the number of children without ADHD.

Values represent quantification of statistical heterogeneity using the *I*^2^ statistic (*P* for heterogeneity of the Cochran Q test) or represent the cohort-specific *P* for interaction between the FT4 SD score and UI/Creat in relation to ADHD.

Values represent quantification of statistical heterogeneity using the *I*^2^ statistic (*P* for heterogeneity of the Cochran Q test) or represent the cohort-specific *P* for interaction between the TSH SD score and UI/Creat in relation to ADHD.

FT4 was not associated with a high autistic-trait score (OR: 1.1; 95% CI: 0.9, 1.2; *P* = 0.27; *I*^2^ = 0.0%; *P* for heterogeneity = 0.27) ([**Table 3**](#tbl3){ref-type="table"}). This association was not modified by UI/Creat (*P* for interaction 0.48, 0.82, and 0.11 in Generation R, INMA, and ALSPAC, respectively). TSH was not associated with a high autistic-trait score (OR: 0.9; 95% CI: 0.8, 1.1; *P* = 0.46; *I*^2^ = 6.2%; *P* for heterogeneity = 0.34) ([Table 3](#tbl3){ref-type="table"}). A statistically significant effect modification by UI/Creat was only seen in INMA (*P* for interaction = 0.007), showing that higher TSH is associated with higher risk of a high autistic-trait score when the mother has UI/Creat \<150 μg/g (OR: 1.7; 95% CI: 1.0, 2.8; *P* = 0.049) ([Table 3](#tbl3){ref-type="table"}). However, when we combined the 3 cohorts using a random-effects meta-analysis, this association was not apparent ([Table 3](#tbl3){ref-type="table"}). Excluding TPOAb-positive women from Generation R and ALSPAC (information on TPOAb status was only available in these 2 cohorts) yielded similar results (data not shown).

###### 

Association of FT4 and TSH with a high autistic-trait score ≥93rd percentile in all mother--child pairs and stratified by groups of UI/Creat^[1](#tb3fn1){ref-type="table-fn"}^

                                           High autistic-trait score ≥93rd percentile                                                                               
  ------------------------- -------------- -------------------------------------------- ---------------- ------- -------------- ---------- ---------------- ------- --------------
  All mother--child pairs   Pooled         255/2920                                     1.1 (0.9, 1.2)   0.27    0.0% (0.27)    210/2441   0.9 (0.8, 1.1)   0.46    6.2% (0.34)
                            Generation R   85/1062                                      1.1 (0.9, 1.3)   0.69    0.48           84/1056    1.0 (0.8, 1.3)   0.81    0.33
                            INMA           88/985                                       1.1 (0.9, 1.4)   0.50    0.82           46/528     1.0 (0.8, 1.3)   0.98    0.007
                            ALSPAC         82/873                                       1.1 (0.9, 1.4)   0.45    0.11           80/857     0.8 (0.6, 1.0)   0.10    0.45
  UI/Creat \<150 μg/g       Pooled         121/1330                                     0.9 (0.7, 1.1)   0.42    0.0% (0.98)    124/1396   1.1 (0.8, 1.6)   0.61    53.8% (0.11)
                            Generation R   21/299                                       1.0 (0.6, 1.6)   0.86    NA             21/297     1.0 (0.6, 1.7)   0.97    NA
                            INMA           42/452                                       0.9 (0.6, 1.4)   0.64    NA             46/528     1.7 (1.0, 2.8)   0.049   NA
                            ALSPAC         58/579                                       0.9 (0.7, 1.2)   0.51    NA             57/571     0.9 (0.7, 1.2)   0.45    NA
  UI/Creat ≥150 μg/g        Pooled         134/1590                                     1.2 (1.0, 1.5)   0.06    13.6% (0.31)   132/1573   0.8 (0.7, 1.0)   0.12    18.1% (0.29)
                            Generation R   64/763                                       1.1 (0.8, 1.4)   0.55    NA             63/759     1.0 (0.8, 1.3)   0.85    NA
                            INMA           46/533                                       1.2 (0.9, 1.7)   0.26    NA             46/528     0.8 (0.5, 1.1)   0.15    NA
                            ALSPAC         24/294                                       1.6 (1.0, 2.5)   0.032   NA             23/286     0.7 (0.4, 1.1)   0.08    NA

The pooled estimate represents the overall effect estimates (OR with 95% CI) calculated with a random-effects meta-analysis. ALSPAC, Avon Longitudinal Study of Parents and Children; FT4, free thyroxine; INMA, INfancia y Medio Ambiente; NA, not applicable; TSH, thyroid-stimulating hormone; UI/Creat, urinary iodine-to-creatinine ratio.

n represents the number of children with a high autistic-trait score ≥93rd percentile; N represents the number of children with an autistic trait score \<93rd percentile.

Values represent quantification of statistical heterogeneity using the *I*^2^ statistic (*P* for heterogeneity of the Cochran Q test) or represent the cohort-specific *P* for interaction between the FT4 SD score and UI/Creat in relation to a high autistic-trait score.

Values represent quantification of statistical heterogeneity using the *I*^2^ statistic (*P* for heterogeneity of the Cochran Q test) or represent the cohort-specific *P* for interaction between the TSH SD score and UI/Creat in relation to a high autistic-trait score.

Discussion {#sec4}
==========

This meta-analysis of individual-participant data from 3 large cohorts showed no consistent evidence to support an association of maternal iodine status with child ADHD or autistic traits in the general population. The association of maternal FT4 with child ADHD was not affected by the iodine status of the mother.

This study was performed against the background of mild-to-moderate iodine deficiency being a common problem among pregnant women ([@bib24]) that has been associated with lower IQ scores ([@bib28]), suboptimal reading accuracy and comprehension ([@bib30]), poorer spelling ([@bib66], [@bib67]), reduced receptive and expressive language skills ([@bib68]), worse executive function ([@bib69]), poorer fine motor skills ([@bib70]), internalizing and externalizing problems ([@bib70]), and higher ADHD symptom scores ([@bib34]). Separate studies within Generation R or INMA reported no evidence for an association between UIC and language comprehension at the age of 6 y ([@bib59]) or cognitive and psychomotor development measured at 1 y of age ([@bib71], [@bib72]). The current meta-analysis of individual-participant data from 3 different studies also finds no support for an association between maternal iodine status and child ADHD or autistic traits.

There may be several explanations as to why no association was observed in this study. Firstly, although use of urinary iodine concentration is recommended to determine population iodine status, it is only a crude proxy for individual iodine status owing to large day-to-day variability ([@bib73], [@bib74]). Although it is assumed that a low excretion of iodine reflects a low recent iodine intake, it is uncertain how well this reflects the ability of a person to utilize the available iodine supply for thyroid hormone synthesis, or whether this reflects an iodine-depleted thyroid. Second, it is suggested that iodine deficiency before preconception and in early pregnancy may constitute a risk factor for neurodevelopmental problems ([@bib28]). Hence, optimal iodine intake needs to be achieved in early pregnancy, and preferably before conception to anticipate the increased need for thyroid hormone production during pregnancy ([@bib75], [@bib76]). On the assumption that the urine collection may have occurred too late in pregnancy, we also investigated the association of iodine status in early pregnancy with neurodevelopmental problems (i.e., ≤18 and ≤14 wk), but maternal iodine status in these early time-windows was also not associated with child ADHD or autistic traits. Third, the clinical relevance of our outcome measures may be debated. Not all 3 cohorts obtained clinical diagnoses of ADHD and ASD, which may have led to (nondifferential) outcome misclassification. Against this, the questionnaires were valid quantitative measures of ADHD symptoms or autistic traits and have been extensively used in epidemiological studies.

Interestingly, only in the Generation R cohort, which is an overall iodine-sufficient population, was "iodine deficiency" associated with a higher risk of ADHD. These associations in the Generation R cohort only may seem counter-intuitive, because at population level, iodine deficiency in this population is relatively less severe and certainly less common than in the INMA or ALSPAC populations. The Netherlands has a well implemented iodine fortification program ([@bib77]). The proportion of households consuming iodized salt is estimated to be 60%--70%, which is relatively high compared with Spain and the UK \[16% and 2%, respectively ([@bib78])\]. As such, an association between maternal iodine deficiency and child neurobehavioral problems might be less likely in Generation R than in INMA or ALSPAC. However, it has previously been suggested that iodine-deficient women with a more sporadic iodine supply may have a more efficient thyroidal uptake of iodine ([@bib79]) and the strength of the association between iodine deficiency and child neurodevelopmental outcomes need not depend on the degree of iodine sufficiency in the population. Racial differences may also contribute to heterogeneity in results across cohorts. The Generation R cohort consists of a multiethnic population, whereas in the INMA and ALSPAC cohorts there is less ethnic variability. Whether genetic variation modifies the association between maternal iodine status and child neurobehavioral problems remains to be investigated.

The association between higher UI/Creat and a higher risk of autistic traits was unexpected. If not a chance finding, then this may be explained by the fact that more-than-adequate or excessive iodine intake in an iodine-replete population has previously been linked to maternal hypothyroidism and hypothyroxinemia ([@bib80]); both of these have also been associated with a higher risk of ASD or autistic traits ([@bib15], [@bib22]). However, we did not identify differences in FT4 or TSH concentrations, or the TPOAb-positivity rates between the "iodine-deficient" group (i.e., UI/Creat \<150 μg/g) and the "iodine-sufficient" group (i.e., UI/Creat ≥150 μg/g). Because iodine and thyroid measures were both taken in pregnancy, there is a possible lag time between low iodine status and impaired thyroid function.

The present study shows that the maternal FT4 concentration during pregnancy was associated with child ADHD, but maternal iodine status did not seem to underpin this association. First, the association between higher FT4 and child ADHD did not reach statistical significance in our previous analysis ([@bib21]), which suggests that conditioning on iodine concentrations may have introduced a selection effect. Second, the cohort-specific analysis showed that, solely in INMA, a higher TSH was associated with a high child autistic-trait score in "iodine-deficient" mothers only. Iodine deficiency may induce TPOAb positivity ([@bib80]), and the presence of these antibodies could potentially lead to impaired thyroid function, including higher TSH. Children born to TPOAb-positive mothers may be at a higher risk of ASD ([@bib81]). Unfortunately, we could not investigate whether TPOAb positivity could explain why there was effect modification in the association between TSH and autistic traits in INMA, because TPOAb titers were not determined in this cohort.

We have performed random-effects meta-analyses because we assumed that differences in effect estimates across cohorts are not due to chance only. Despite having used individual-participant data to harmonize the analysis across cohorts, some degree of heterogeneity is inevitable. We previously discussed different factors that could contribute to heterogeneity in the results across cohorts, including the differing ages at assessment, types of evaluators (i.e., parents or teachers), and methodologies ([@bib21], [@bib23]). We explored and quantified the statistical heterogeneity. A high percentage of *I*^2^ (i.e., ≥75%) typically indicates that studies are highly heterogeneous and in the absence of strict criteria, it is up to the meta-analyst to decide whether the meta-analysis is meaningful or if it is better to present the cohort-specific effect estimates only ([@bib82]). In the present study, several meta-analyses showed moderate statistical heterogeneity (i.e., *I*^2^ ∼50%). The only meta-analysis with a high *I*^2^ of 77.7% was that of the association of maternal UI/Creat with child autistic traits in the subgroup with ≥1 measure of UI/Creat in the first 14 wk of pregnancy. This finding should therefore be interpreted with caution.

This study enabled us to investigate the association of maternal iodine status during pregnancy with child neurobehavioral problems in a large population-based sample and to examine the heterogeneity of results across cohorts. This study has several potential limitations. Firstly, although the sample size was large enough to evaluate the iodine status of the population from 1--4 spot urine samples, this is insufficient for assessing individual iodine status ([@bib73], [@bib83]). Second, there is variability between urinary iodine measurements undertaken in different laboratories ([@bib84]); however, the 3 laboratories that measured samples from these cohorts used certified reference materials to ensure accurate measurements. Next, the ascertainment of ADHD and autistic traits was performed at different ages by different instruments and evaluators, which may have introduced "noise" and heterogeneity. Furthermore, we had no medical-record data to confirm ADHD or ASD diagnosis or data on therapeutic drug use by the children in the study. Lastly, this meta-analysis was not conducted in the context of a systematic review. Ideally, meta-analyses of individual participant data should be performed by a systematic review that searches for both published and unpublished studies ([@bib85]).

To conclude, no consistent evidence for an association of maternal iodine status with child ADHD and autistic traits was found across cohorts with differing iodine status.

Supplementary Material
======================

###### 

Click here for additional data file.
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